APPLICATION
NDA214313
TYPE
NDA
ORIGINAL APPROVAL
2021-01-15
LATEST ACTION
2026-02-06
ROUTE
INTRAVENOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription
Products
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE · ReferencePrescription
NOREPINEPHRINE BITARTRATE EQ 8MG BASE/250ML (EQ 32MCG BASE/ML) · SOLUTION · INTRAVENOUS
NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE · ReferencePrescription
NOREPINEPHRINE BITARTRATE EQ 16MG BASE/250ML (EQ 64MCG BASE/ML) · SOLUTION · INTRAVENOUS
NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE · ReferencePrescription
NOREPINEPHRINE BITARTRATE EQ 4MG BASE/250ML (EQ 16MCG BASE/ML) · SOLUTION · INTRAVENOUS
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE · ReferencePrescription
NOREPINEPHRINE BITARTRATE EQ 16MG BASE/250ML (EQ 64MCG BASE/ML) · SOLUTION · INTRAVENOUS
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE · ReferencePrescription
NOREPINEPHRINE BITARTRATE EQ 4MG BASE/250ML (EQ 16MCG BASE/ML) · SOLUTION · INTRAVENOUS
NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE · ReferencePrescription
NOREPINEPHRINE BITARTRATE EQ 8MG BASE/250ML (EQ 32MCG BASE/ML) · SOLUTION · INTRAVENOUS
Approval history
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.